GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

INGAP-Peptide

Company
Exsulin Corporation
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT00034255

    Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients

    Not yet reported, Not yet reported GMP Endotherapeutics 62 participants 4 sites
    Type 2 diabetes Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT00071409

    Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes

    Not yet reported Exsulin Corporation 63 participants Est. completion 2004-05 10 sites Stand-alone
    Other conditions: Diabetes Mellitus, Insulin-Dependent
    View official trial listing →
  • Completed NCT NCT00071422

    Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes

    Not yet reported Exsulin Corporation 126 participants Est. completion 2004-06 17 sites Stand-alone
    Other conditions: Diabetes Mellitus, Non-Insulin-Dependent
    View official trial listing →
  • Terminated NCT NCT00995540

    Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults

    Not yet reported Exsulin Corporation 23 participants Est. completion 2011-12 2 sites
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02204397

    Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis

    Not yet reported Jewish General Hospital 5 participants Est. completion 2017-03-08 1 site
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02538848

    Study of HTD4010 in Healthy Volunteers

    Not yet reported HighTide Therapeutics (Hong Kong) Limited 32 participants Est. completion 2016-03 1 site
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.